Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), has completed its $16.5 billion, all-cash acquisition of contract development and manufacturing firm Catalent (CLCT), the companies said on Wednesday.
Under terms of the transaction, Catalent shareholders received $63.50 in cash for each of their share, a premium of around 47.5% to the volume-weighted average price of the stock prior to the deal being announced in early February.
Catalent shares stopped trading on Wednesday and are being delisted from the New York Stock Exchange, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。